{"id":462,"date":"2026-08-28T06:56:05","date_gmt":"2026-08-28T06:56:05","guid":{"rendered":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"survodutide-synchronize-1-2026-phase-3-data","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/survodutide-synchronize-1-2026-phase-3-data\/","title":{"rendered":"Survodutide en SYNCHRONIZE-1: La fase 2026 N\u00fameros 3 en contexto"},"content":{"rendered":"<p class=\"pim-standfirst wp-block-paragraph\">SYNCHRONIZE-1 es el mayor ensayo sobre obesidad con survodutida publicado hasta la fecha. La evidencia \u00fatil est\u00e1 en el denominador completo, la estimaci\u00f3n, la respuesta al placebo y el patr\u00f3n de eventos adversos, no en un solo porcentaje general.<\/p><div class=\"wp-block-group pim-key-takeaways\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><h2 class=\"wp-block-heading\">Lo que muestra el registro<\/h2><ul class=\"wp-block-list\"><li>El ensayo aleatoriz\u00f3 a adultos 725 con obesidad sin diabetes.<\/li><li>En la semana 76, el cambio de peso medio fue \u221212.2% y \u221213.0% en los dos grupos de survodutida versus \u22125.4% con placebo.<\/li><li>Se produjeron eventos adversos gastrointestinales en 80.9% y 89.7% de los participantes con survodutida versus 47.9% con placebo.<\/li><\/ul><\/div><\/div><figure class=\"wp-block-image size-full pim-article-figure\"><img loading=\"lazy\" decoding=\"async\" width=\"1536\" height=\"1024\" src=\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png\" alt=\"Cient\u00edfico revisando datos de ensayos metab\u00f3licos y dos v\u00edas de se\u00f1alizaci\u00f3n de receptores\" class=\"wp-image-457\" srcset=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828.png 1536w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-300x200.png 300w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-1024x683.png 1024w, https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/survodutide-dual-receptor-research-20260828-768x512.png 768w\" sizes=\"auto, (max-width: 1536px) 100vw, 1536px\" \/><figcaption class=\"wp-element-caption\">Ilustraci\u00f3n editorial original del contexto de la investigaci\u00f3n. No es una figura de estudio, una imagen de un paciente, una fotograf\u00eda del producto suministrado ni una representaci\u00f3n de material de prueba.<\/figcaption><\/figure><h2 class=\"wp-block-heading\">Registro de estudio<\/h2><p class=\"wp-block-paragraph\">La estimaci\u00f3n del r\u00e9gimen de tratamiento inform\u00f3 cambios medios de \u221212.2% (95% CI, \u221213.6 a \u221210.8) y \u221213.0% (95% CI, \u221214.4 a \u221211.6), en comparaci\u00f3n con \u22125.4% (95%) CI, \u22126.9 a \u22124.0) para placebo. Ambas comparaciones activas fueron estad\u00edsticamente significativas.<\/p><div class=\"wp-block-group pim-evidence-table\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\"><div class=\"pim-evidence-row\"><strong>Dise\u00f1o<\/strong><span>Ensayo 3 en fase aleatorizado, doble ciego y controlado con placebo<\/span><\/div><div class=\"pim-evidence-row\"><strong>Participantes<\/strong><span>725; edad media 47.1 a\u00f1os; media BMI 37.9<\/span><\/div><div class=\"pim-evidence-row\"><strong>Resultado semanal-76<\/strong><span>\u221212.2%, \u221213.0% y \u22125.4% cambio de peso medio<\/span><\/div><div class=\"pim-evidence-row\"><strong>Al menos reducci\u00f3n 5%<\/strong><span>72.6%, 71.9% y 46.3%<\/span><\/div><div class=\"pim-evidence-row\"><strong>Fallecidos<\/strong><span>Ninguno informado en el ensayo publicado.<\/span><\/div><\/div><\/div><h2 class=\"wp-block-heading\">Resultados en contexto<\/h2><p class=\"wp-block-paragraph\">El criterio de valoraci\u00f3n del respondedor \u22655% apunta en la misma direcci\u00f3n, pero el grupo de placebo tambi\u00e9n tuvo una respuesta sustancial. Esto es importante porque todos los grupos participaron en un ensayo controlado en lugar de una comparaci\u00f3n sin intervenci\u00f3n.<\/p><p class=\"wp-block-paragraph\">El documento llama a la survodutida en investigaci\u00f3n. No establece intercambiabilidad entre la formulaci\u00f3n de prueba y un material de cat\u00e1logo de origen independiente.<\/p><h2 class=\"wp-block-heading\">Lo que este estudio no puede responder<\/h2><p class=\"wp-block-paragraph\">Los participantes no ten\u00edan diabetes, por lo que el resultado no debe generalizarse a todas las poblaciones metab\u00f3licas.<\/p><p class=\"wp-block-paragraph\">El art\u00edculo 3 de una fase no puede responder preguntas sobre el uso a largo plazo posterior a la aprobaci\u00f3n, eventos raros o un lote de investigaci\u00f3n no relacionado.<\/p>","protected":false},"excerpt":{"rendered":"<p>SYNCHRONIZE-1 es el mayor ensayo sobre obesidad con survodutida publicado hasta la fecha. La evidencia \u00fatil est\u00e1 en el denominador completo, la estimaci\u00f3n, la respuesta al placebo y el patr\u00f3n de eventos adversos, no en un solo porcentaje general.<\/p>","protected":false},"author":1,"featured_media":627,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"365","pim_article_type":"Published study case","pim_evidence_level":"Randomized phase 3 human trial; investigational intervention","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-28","pim_editorial_note":"Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Survodutide Once Weekly for Adults with Obesity \u2014 SYNCHRONIZE-1\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42253238\/\",\"note\":\"2026 phase 3 primary record; PMID 42253238.\"},{\"title\":\"Survodutide phase 2 obesity trial\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/38330987\/\",\"note\":\"Dose-ranging clinical context; PMID 38330987.\"},{\"title\":\"ClinicalTrials.gov NCT06066515\",\"url\":\"https:\/\/clinicaltrials.gov\/study\/NCT06066515\",\"note\":\"Registry record for SYNCHRONIZE-1.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD<\/title>\n<meta name=\"description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/survodutide-synchronize-1-2026-phase-3-data\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\" \/>\n<meta property=\"og:description\" content=\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/survodutide-synchronize-1-2026-phase-3-data\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T06:56:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"},\"wordCount\":248,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\",\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"datePublished\":\"2026-08-28T06:56:05+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/survodutide-synchronize-1-2026-phase-3-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Survodutide en SYNCHRONIZE-1: La Fase 2026 N\u00fameros 3 en Contexto - NHD","description":"SYNCHRONIZE-1 es el mayor ensayo sobre obesidad con survodutida publicado hasta la fecha. La evidencia \u00fatil est\u00e1 en el denominador completo, estimaci\u00f3n, respuesta al placebo y...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/survodutide-synchronize-1-2026-phase-3-data\/","og_locale":"es_ES","og_type":"article","og_title":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","og_description":"SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response an\u2026","og_url":"https:\/\/nhdbio.com\/es\/survodutide-synchronize-1-2026-phase-3-data\/","og_site_name":"NHD","article_published_time":"2026-08-28T06:56:05+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"},"wordCount":248,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","articleSection":["Published Study Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","url":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/","name":"Survodutide en SYNCHRONIZE-1: La Fase 2026 N\u00fameros 3 en Contexto - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","datePublished":"2026-08-28T06:56:05+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"SYNCHRONIZE-1 es el mayor ensayo sobre obesidad con survodutida publicado hasta la fecha. La evidencia \u00fatil est\u00e1 en el denominador completo, estimaci\u00f3n, respuesta al placebo y...","breadcrumb":{"@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/survodutide-synchronize-1-2026-phase-3-data-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/survodutide-synchronize-1-2026-phase-3-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Survodutide in SYNCHRONIZE-1: The 2026 Phase 3 Numbers in Context"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=462"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/462\/revisions"}],"predecessor-version":[{"id":514,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/462\/revisions\/514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/627"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}